Success Metrics

Clinical Success Rate
88.3%

Based on 68 completed trials

Completion Rate
88%(68/77)
Active Trials
6(6%)
Results Posted
28%(19 trials)
Terminated
9(10%)

Phase Distribution

Ph not_applicable
11
12%
Ph early_phase_1
1
1%
Ph phase_2
21
22%
Ph phase_3
12
13%
Ph phase_4
21
22%
Ph phase_1
7
7%

Phase Distribution

8

Early Stage

21

Mid Stage

33

Late Stage

Phase Distribution73 total trials
Early Phase 1First-in-human
1(1.4%)
Phase 1Safety & dosage
7(9.6%)
Phase 2Efficacy & side effects
21(28.8%)
Phase 3Large-scale testing
12(16.4%)
Phase 4Post-market surveillance
21(28.8%)
N/ANon-phased studies
11(15.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.3%

68 of 77 finished

Non-Completion Rate

11.7%

9 ended early

Currently Active

6

trials recruiting

Total Trials

94

all time

Status Distribution
Active(7)
Completed(68)
Terminated(9)
Other(10)

Detailed Status

Completed68
unknown10
Terminated9
Recruiting5
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
94
Active
6
Success Rate
88.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.4%)
Phase 17 (9.6%)
Phase 221 (28.8%)
Phase 312 (16.4%)
Phase 421 (28.8%)
N/A11 (15.1%)

Trials by Status

unknown1011%
not_yet_recruiting11%
recruiting55%
terminated910%
active_not_recruiting11%
completed6872%

Recent Activity

Clinical Trials (94)

Showing 20 of 94 trialsScroll for more
NCT05294588Phase 2

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Completed
NCT06336317Phase 4

Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE

Recruiting
NCT07259252Not Applicable

Influenza Vaccination After Acute Coronary Syndrome

Recruiting
NCT06279871Phase 3

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

Completed
NCT05074303Phase 2

Beta-glucan and Immune Response to Influenza Vaccine

Completed
NCT06864143Phase 2

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Completed
NCT06355232Phase 1

Covid-19 and Influenza Oral Vaccine Study

Recruiting
NCT03323112

Immune Responses in Health Care Personnel

Recruiting
NCT06141655Phase 4

HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia

Completed
NCT05584735

Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

Completed
NCT07071701

A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population

Completed
NCT06097273Phase 3

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Completed
NCT03955991Phase 4

VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)

Completed
NCT05091307Phase 3

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

Completed
NCT02623075

Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients

Completed
NCT06738082

Influenza Vaccine Elicited Immune Response in Immunocompromised Patients

Completed
NCT06716567Phase 4

Maternal Determinants of Immunity to Influenza

Completed
NCT06041867Not Applicable

Agaricus Bisporus and Influenza Vaccination Response

Completed
NCT03748524Early Phase 1

Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine

Completed
NCT05654441Phase 4

Body and Social Behavior

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
94